RAD-x continues Buy & Build with acquisition of Swiss Medical Imaging Centers - Gilde Healthcare

RAD-x continues Buy & Build with acquisition of Swiss Medical Imaging Centers

February 13, 2018

Utrecht, The Netherlands – RAD-x, a France-based operator in diagnostic imaging and a portfolio company of Gilde Healthcare, announced that it has acquired Swiss Medical Imaging Investment SA (SMII), which operates the imaging centres Centre d’Imagerie Médicale de la Chaux-de-Fonds, Centre d’Imagerie Médicale du Chablais and Centre d’Imagerie Médicale du Chablais Valaisan.

SMII is a leading diagnostic imaging provider in the Swiss cantons of Neuchâtel, Vaud and Valais and was founded and developed by the radiology entrepreneur Dr. Pierre Chevalley, who as part of this transaction becomes a shareholder in RAD-x.

With the acquisition of SMII, RAD-x expands its national reach and capabilities and strengthens its position as the partner of choice for diagnostic imaging centres and radiologists by combining medical excellence with state of the art management capabilities. With this transaction RAD-x is now able to offer the full range of imaging services from general to very specialized imaging as well as interventional radiology. Next to its expansion in Switzerland, RAD-x is progressing on its development in Germany and France.

 

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and Dach-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Since 2001 Gilde Healthcare has raised €800 million ($1 billion) for its specialized funds. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022